Lupin unveils Contraceptive drug Merzee in US
Merzee, 1 mg/20 mcg is a generic equivalent of Taytulla, 1 mg/20mcg of Allergan Pharmaceuticals International Limited.
Mumbai: Global pharma major, Lupin Limited, has announced that the company has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, a medication used to prevent pregnancy, in the US market.
The company has launched the product under an exclusive license, marketing, and distribution agreement with Slayback Pharma LLC.
Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International Limited.
Slayback had earlier launched this product in the US in February 2021.
Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of USD 90 million in the U.S.
Read also: Lupin concludes purchase of brands from Anglo-French
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.
Read also: Lupin joins hands with Alvion to commercialize Cardiometabolic medicines in Southeast Asia
Slayback Pharma is a Princeton, NJ headquartered, specialty pharmaceutical company focused on the development and commercialization of complex ANDAs and patent-protected NDAs. The company is backed by highly-regarded private equity investors, KKR and Everstone, who committed USD 60 million and USD 50 million in financing in December 2016 and December 2019 respectively.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.